Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy : A comprehensive review

Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called "cytokine storm". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19

Year of Publication: 2020
Contained in: Autoimmunity reviews Vol. 19, No. 7 (2020), p. 102569
All journal articles: Search for all articles in this journal
Language: English
Contributors: Alijotas-Reig, Jaume | Author
Esteve-Valverde, Enrique
Belizna, Cristina
Selva-O'Callaghan, Albert
Pardos-Gea, Josep
Quintana, Angela
Mekinian, Arsene
Anunciacion-Llunell, Ariadna
Miró-Mur, Francesc
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Acute respiratory distress syndrome
COVID-19
Cytokine storm
EC 2.7.10.2
Immunosuppressive
Journal Article
Review
SARS-CoV-2
Treatment
Additional Keywords: *Immunomodulation
Angiotensin-Converting Enzyme Inhibitors
Anticoagulants
Antimalarials
Antiviral Agents
Betacoronavirus
Coronavirus Infections
Cytokines
Glucocorticoids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Immunoglobulins, Intravenous
Janus Kinases
Pandemics
Pneumonia, Viral
Risk Factors
ISSN: 1873-0183
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 10.06.2020
Date Revised 10.06.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32376394
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.autrev.2020.102569
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 05162nma a2201093 c 4500
001 NLM310461316
003 DE-601
005 20200611213828.0
007 cr uuu---uuuuu
008 200507s2020 000 0 eng d
024 7 |a 10.1016/j.autrev.2020.102569  |2 doi 
028 5 2 |a pubmed20n1228.xml 
035 |a S1568-9972(20)30131-2 
035 |a (DE-599)NLM32376394 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Alijotas-Reig, Jaume 
245 1 0 |a Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy  |h Elektronische Ressource  |b A comprehensive review 
300 |a Online-Ressource 
500 |a Date Completed 10.06.2020 
500 |a Date Revised 10.06.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020. Published by Elsevier B.V. 
520 |a Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called "cytokine storm". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Angiotensin-Converting Enzyme Inhibitors  |6 D000806  |a therapeutic use  |6 Q000627 
653 2 |a Anticoagulants  |6 D000925  |a therapeutic use  |6 Q000627 
653 2 |a Antimalarials  |6 D000962  |a therapeutic use  |6 Q000627 
653 2 |a Antiviral Agents  |6 D000998 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a Coronavirus Infections  |6 D018352  |a *therapy  |6 Q000628 
653 2 |a Cytokines  |6 D016207  |a antagonists & inhibitors  |6 Q000037 
653 2 |a Glucocorticoids  |6 D005938  |a therapeutic use  |6 Q000627 
653 2 |a Humans  |6 D006801 
653 2 |a Hydroxymethylglutaryl-CoA Reductase Inhibitors  |6 D019161  |a therapeutic use  |6 Q000627 
653 2 |a Immunoglobulins, Intravenous  |6 D016756  |a therapeutic use  |6 Q000627 
653 2 |a *Immunomodulation  |6 D056747 
653 2 |a Janus Kinases  |6 D053612  |a antagonists & inhibitors  |6 Q000037 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *therapy  |6 Q000628 
653 2 |a Risk Factors  |6 D012307 
655 7 |a Acute respiratory distress syndrome  |2 gnd 
655 7 |a COVID-19  |2 gnd 
655 7 |a Cytokine storm  |2 gnd 
655 7 |a Immunosuppressive  |2 gnd 
655 7 |a SARS-CoV-2  |2 gnd 
655 7 |a Treatment  |2 gnd 
655 7 |a Angiotensin-Converting Enzyme Inhibitors  |2 gnd 
655 7 |a Anticoagulants  |2 gnd 
655 7 |a Antimalarials  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Cytokines  |2 gnd 
655 7 |a Glucocorticoids  |2 gnd 
655 7 |a Hydroxymethylglutaryl-CoA Reductase Inhibitors  |2 gnd 
655 7 |a Immunoglobulins, Intravenous  |2 gnd 
655 7 |a Janus Kinases  |2 gnd 
655 7 |a EC 2.7.10.2  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a Acute respiratory distress syndrome 
689 1 1 |a COVID-19 
689 1 2 |a Cytokine storm 
689 1 3 |a Immunosuppressive 
689 1 4 |a SARS-CoV-2 
689 1 5 |a Treatment 
689 1 |5 DE-601 
689 2 0 |a Angiotensin-Converting Enzyme Inhibitors 
689 2 1 |a Anticoagulants 
689 2 2 |a Antimalarials 
689 2 3 |a Antiviral Agents 
689 2 4 |a Cytokines 
689 2 5 |a Glucocorticoids 
689 2 6 |a Hydroxymethylglutaryl-CoA Reductase Inhibitors 
689 2 7 |a Immunoglobulins, Intravenous 
689 2 8 |a Janus Kinases 
689 2 9 |A r  |a EC 2.7.10.2 
689 2 |5 DE-601 
700 1 |a Esteve-Valverde, Enrique 
700 1 |a Belizna, Cristina 
700 1 |a Selva-O'Callaghan, Albert 
700 1 |a Pardos-Gea, Josep 
700 1 |a Quintana, Angela 
700 1 |a Mekinian, Arsene 
700 1 |a Anunciacion-Llunell, Ariadna 
700 1 |a Miró-Mur, Francesc 
773 0 8 |i in  |t Autoimmunity reviews  |g Vol. 19, No. 7 (2020), p. 102569  |q 19:7<102569  |w (DE-601)NLM126100284  |x 1873-0183 
856 4 1 |u http://dx.doi.org/10.1016/j.autrev.2020.102569  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 19  |j 2020  |e 7  |b 04  |c 07  |h 102569